Some stocks are one-hit wonders, making a big splash when they first appear, then quickly fizzling into obscurity or oblivion. But for other stocks, that initial big move is only a preview of even bigger and better gains.

Today, we've listed three stocks that made some of the biggest moves up over the past month, which we'll pair with the ratings issued by our Motley Fool CAPS community. The higher each stock's rating, the greater CAPS members' faith in that company's ability to keep on beating the market.

Stock

1-Month Change^

CAPS Rating
(out of 5)

Nymox Pharmaceutical (Nasdaq: NYMX)

33.0%

**

Cirrus Logic (Nasdaq: CRUS)

26.3%

****

Sprint Nextel (NYSE: S)

25.1%

***

^From April 26 to May 25.

As the markets whipsaw to changes in consumer sentiment, there will be weeks like this one when it's hard to believe any company recorded a positive performance. So before we get shaken out again, let's see why the CAPS community thinks these companies might continue to outperform the market.

A mighty temblor
The rush of positive releases about its novel treatment for an enlarged prostate, NX-1207, over the past few weeks would suggest Nymox Pharmaceutical won't be flying under Wall Street's radar much longer. But even if it makes it through the pivotal phase 3 clinical trials, NX-1207 doesn't have a lock on being a blockbuster.

Pfizer (NYSE: PFE) and Abbott Labs make alpha blockers, a common treatment for the same ailment, while 5-alpha reductase inhibitors, such as those produced by GlaxoSmithKline and Merck (NYSE: MRK), are an alternative treatment.

It won't be simple to take on these industry giants even if, as Nymox says, a single dose of NX-1207 has been found to produce symptomatic improvements about double those reported for competing treatments without causing the same sexual or cardiovascular side effects the others do. If the drug does prove to be as successful as claimed, I guess we would see one of the big pharmas make a bid to partner with Nymox, if not buy the company outright.

While they generally believe Nymox can beat the market, nearly 39% of CAPS members rating the company remain skeptical. The two-star rating Nymox carries suggests they believe there are better places for your money. Head over to the Nymox Pharmaceutical CAPS page and give us your prognosis on its future.

Does it compute?
At least one analyst is predicting that Apple (Nasdaq: AAPL) will ramp up production of its iPad to 2.5 million units a month later this year, up from the 1 million to 1.5 million it produces now. So it's easy to see why the market is suddenly smitten with Cirrus Logic, which generates a good chunk of its revenue from the tablet computer as well as Apple's iPhone. Shares of the specialized chip maker have nearly doubled so far this year and are up more than 250% over the past 12 months.

CAPS members are warming up to the company's potential; Futz135 says that the long-rumored Verizon iPhone would only help.

A key component to all of apples new products from ipod, ipad, iphone and their laptops. With verizon looking to offer the iphone this should be a good play from that new demand

Still feeling the aftershocks
With the first functioning 4G network up and running, Sprint Nextel is looking to lose no ground to Verizon or AT&T (NYSE: T), increasing the stakes with the first phone out for the network -- the Evo 4G. That head start should benefit Sprint's bottom line if consumers and investors return to this beaten-down carrier.

Sprint's fortunes have attracted investors like CAPS member huarngpa, who anticipates some groundbreaking deals.

I think we're going to see a turn-around in Sprint-Nextel based on how they are positioning themselves with their service and uptake on the droid frenzy/perhaps possible working out a deal with apple this company is going to make a huge recovery!

Shake, rattle, and roll
With these stocks shaking the market this past month, it pays to start your own research on them at Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.

Pfizer and Sprint Nextel are Motley Fool Inside Value picks. Apple is a Stock Advisor selection. The Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings. You can shake, rattle, and roll The Motley Fool's disclosure policy, but it still won't break.